Printer friendly version Share

News Release

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

26 June 2014 European Society for Medical Oncology (ESMO)

Please login or register to view articles older than 3 months

New Norwegian logo eNEWS-Jan 2017 FNSF ad Cambridge grey garduated Elhuyar with Basque expertsvar 2015